Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company is a leader in the neuroscience space, having launched the first FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Acadia's strategy centers on maximizing its commercial franchises while advancing a robust pipeline of next-generation antipsychotics and treatments for neurodegenerative conditions. The company operates primarily out of San Diego, California, and has recently expanded its global footprint with regulatory filings in Canada, Israel, and the European Union.